Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: Implications for novel mGluR-based therapeutics

Journal of Psychiatry and Neuroscience

Volumn 39, Issue 6, 2014, Pages 407-416

  Matosin, Natalie ^a,b,c   Fernandez Enright, Francesca ^a,b,c   Frank, Elisabeth ^a,b,c   Deng, Chao ^a,b,c   Wong, Jenny ^a,b   Huang, Xu Feng ^a,b,c   Newell, Kelly A ^a,b,c  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b ILLAWARRA HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^c SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL) PROPIONIC ACID; 2 METHYL 6 (PHENYLETHYNYL) PYRIDINE; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 5; UNCLASSIFIED DRUG; GRM5 PROTEIN, HUMAN;

ANTERIOR CINGULATE; ARTICLE; AUTORADIOGRAPHY; BIPOLAR DISORDER; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; DELUSION; DEMOGRAPHY; DEPRESSION; DEPRESSIVE PSYCHOSIS; EMOTION; FEMALE; HUMAN; HUMAN TISSUE; MALE; MOOD; NEUROPATHOLOGY; RECEPTOR BINDING; SCHIZOPHRENIA; ADULT; AGING; CINGULATE GYRUS; COHORT ANALYSIS; COMPARATIVE STUDY; MAJOR DEPRESSION; METABOLISM; MIDDLE AGED; PSYCHOSIS; YOUNG ADULT;

ADULT; AGING; AUTORADIOGRAPHY; BIPOLAR DISORDER; COHORT STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; GYRUS CINGULI; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RECEPTOR, METABOTROPIC GLUTAMATE 5; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84908271476     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.130242     Document Type: Article

References (47)

1. Machado-Vieira R, Ibrahim L, Henter ID, et al. Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav 2012;100:678-87.
2. Rothschild AJ. Challenges in the treatment of major depressive disorder with psychotic features. Schizophr Bull 2013;39:787-96.
3. Gasquoine PG. Localization of function in anterior cingulate cortex: From psychosurgery to functional neuroimaging. Neurosci Biobehav Rev 2013;37:340-8.
4. Auer DP, Pütz B, Kraft E, et al. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 2000;47:305-13.
5. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007;62:1310-6.
6. Théberge J, Al-Semaan Y, Williamson PC, et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 2003;160:2231-3.
7. Kristiansen LV, Beneyto M, Haroutunian V, et al. Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Mol Psychiatry 2006;11:737-47.
8. Woo T-U, Walsh JP, Benes FM. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry 2004;61:649-57.
9. Zhao J, Bao A-M, Qi X-R, et al. Gene expression of GABA and glutamate pathway markers in the prefrontal cortex of non-suicidal elderly depressed patients. J Affect Disord 2012;138:494-502.
10. Nicoletti F, Bockaert J, Collingridge GL, et al. Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology 2011;60:1017-41.
11. Matosin N, Newell KA. Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia. Neurosci Biobehav Rev 2013;37:256-68.
12. Newell KA, Matosin N, Lum JS. Metabotropic glutamate receptors in the pathophysiology and treatment of schizophrenia and major depression. In: Foster Olive M, editor. Metabotropic glutamate receptors: molecular mechanisms, role in neurological disorders and pharmacological effects. Hauppauge (NY): Nova; 2014.
13. Vinson PN, Conn JP. Metabotropic glutamate receptors as therapeutic targets for schizophrenia. Neuropharmacology 2012;62:1461-72.
14. Kovacevic T, Skelin I, Minuzzi L, et al. Reduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: an autoradiographic study. Brain Res Bull 2012;87:406-12.
15. Wieronska JM, Branski P, Szewczyk B, et al. Changes in the expression of metabotropic glutamate receptor 5 (mGluR5) in the rat hippocampus in an animal model of depression. Pol J Pharmacol 2001;53:659-62.
16. Torrey EF, Webster M, Knable M, et al. The Stanley Foundation brain collection and Neuropathology Consortium. Schizophr Res 2000;44:151-5.
17. Martins-de-Souza D, Guest PC, Harris LW, et al. Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. Transl Psychiatry 2012;2:e87.
18. Richards G, Messer J, Malherbe P, et al. Distribution and abundance of metabotropic glutamate receptor subtype 2 in rat brain revealed by [3H]LY354740 binding in vitro and quantitative radioautography: correlation with the sites of synthesis, expression, and agonist stimulation of [35S]GTPγs binding. J Comp Neurol 2005;487:15-27.
19. Frank E, Newell KA, Huang XF. Density of metabotropic glutamate receptors 2 and 3 (mGluR2/3) in the dorsolateral prefrontal cortex does not differ with schizophrenia diagnosis but decreases with age. Schizophr Res 2011;128:56-60.
20. Samadi P, Grégoire L, Morissette M, et al. mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Aging 2008;29:1040-51.
21. Matosin N, Frank E, Deng C, et al. Metabotropic glutamate receptor 5 binding and protein expression in schizophrenia and following antipsychotic drug treatment. Schizophr Res 2013;146:170-6.
22. Kim S, Webster MJ. The stanley neuropathology consortium integrative database: a novel, web-based tool for exploring neuropathological markers in psychiatric disorders and the biological processes associated with abnormalities of those markers. Neuropsychopharmacology 2010;35:473-82.
23. Kim S, Zavitsanou K, Gurguis G, et al. Neuropathology markers and pathways associated with molecular targets for antipsychotic drugs in postmortem brain tissues: exploration of drug targets through the Stanley Neuropathology Integrative Database. Eur Neuropsychopharmacol 2012;22:683-94.
24. Feyissa AM, Woolverton WL, Miguel-Hidalgo JJ, et al. Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:279-83.
25. Deschwanden A, Karolewicz B, Feyissa AM, et al. Reduced metabotropic glutamate receptor 5 density in major depression determined by [11C] ABP688 PET and postmortem study. Am J Psychiatry 2011;168:727-34.
26. Bernard R, Kerman IA, Thompson RC, et al. Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol Psychiatry 2011;16:634-46.
27. Crook JM, Akil M, Law BCW, et al. Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects. Mol Psychiatry 2002;7:157-64.
28. Gupta DS, McCullumsmith RE, Beneyto M, et al. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 2005;57:123-31.
29. Ohnuma T, Augood SJ, Arai H, et al. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res Mol Brain Res 1998;56:207-17.
30. Richardson-Burns SM, Haroutunian V, Davis KL, et al. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol Psychiatry 2000;47:22-8.
31. Volk DW, Eggan SM, Lewis DA. Alterations in metabotropic glutamate receptor 1a and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia. Am J Psychiatry 2010;167:1489-98.
32. Fatemi SH, Folsom TD, Rooney RJ, et al. mRNA and protein expression for novel GABAA receptors θ and ρ2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway. Transl Psychiatry 2013;3:e271.
33. Newell KA, Matosin N. Rethinking metabotropic glutamate receptor 5 pathological findings in psychiatric disorders: implications for the future of novel therapeutics. BMC Psychiatry 2014;14:23.
34. Tascedda F, Blom JMC, Brunello N, et al. Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. Biol Psychiatry 2001;50:117-22.
35. Matrisciano F, Storto M, Ngomba RT, et al. Imipramine treatment up-regulates the expression and function of mGlu2/3 metabotropic glutamate receptors in the rat hippocampus. Neuropharmacology 2002; 42:1008-15.
36. Smiałowska M, Szewczyk B, Branski P, et al. Effect of chronic imipramine or electroconvulsive shock on the expression of mGluR1a and mGluR5a immunoreactivity in rat brain hippocampus. Neuropharmacology 2002;42:1016-23.
37. Newell KA. Metabotropic glutamate receptor 5 in schizophrenia: emerging evidence for the development of antipsychotic drugs. Future Med Chem 2013;5:1471-4.
38. Liu W, Downing ACM, Munsie LM, et al. Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia. Pharmacogenomics J 2012;12:246-54.
39. Jeste DV, Maglione JE. Treating older adults with schizophrenia: challenges and opportunities. Schizophr Bull 2013;39:966-8.
40. Zavitsanou K, Ward PB, Huang XF. Selective alterations in ionotropic glutamate receptors in the anterior cingulate cortex in schizophrenia* 1. Neuropsychopharmacology 2002;27:826-33.
41. Koethe D, Llenos IC, Dulay JR, et al. Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm 2007;114:1055-63.
42. Bhagwagar Z, Wylezinska M, Jezzard P, et al. Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int J Neuropsychopharmacol 2008;11:255-60.
43. Kelly TM, Daley DC, Douaihy AB. Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav 2012;37:11-24.
44. Farrell M, Howes S, Taylor C, et al. Substance misuse and psychiatric comorbidity: an overview of the OPCS National Psychiatric Morbidity Survey. Int Rev Psychiatry 2003;15:43-9.
45. Kupila J, Kärkkäinen O, Laukkanen V, et al. mGluR1/5 receptor densities in the brains of alcoholic subjects: a whole-hemisphere autoradiography study. Psychiatry Res 2013;212:245-50.
46. Meinhardt MW, Hansson AC, Perreau-Lenz S, et al. Rescue of infralimbic mGluR2 deficit restores control over drug-seeking behavior in alcohol dependence. J Neurosci 2013;33:2794-806.
47. Olive MF. Metabotropic glutamate receptor ligands as potential therapeutics for addiction. Curr Drug Abuse Rev 2009;2:83-98.